Research Topics
| E R DorseySummaryAffiliation: University of Rochester Country: USA Publications
| Collaborators
|
Detail Information
Publications
Funding of Parkinson research from industry and US federal and foundation sourcesE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 24:731-7. 2009..These companies will likely require partnerships to drive successful development of new PD therapies...
Financing of U.S. biomedical research and new drug approvals across therapeutic areasE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York, United States of America
PLoS ONE 4:e7015. 2009..We estimated U.S. biomedical research funding across therapeutic areas, determined the association with disease burden, and evaluated new drug approvals that resulted from this investment...- The economics of new faculty hires in basic scienceE Ray Dorsey
University of Rochester School of Medicine and Dentistry, University of Rochester, Rochester, New York 14620, USA
Acad Med 84:26-31. 2009..To compare the streams of expenses and revenues associated with investment in a cohort of basic science investigators at the University of Rochester School of Medicine & Dentistry for seven years... - Communicating clinical trial results to research participantsE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Ave, Ste 223, Rochester, NY 14620, USA
Arch Neurol 65:1590-5. 2008..Communicating clinical trial results to research participants is seldom accomplished in a timely or an effective manner... - Funding of US biomedical research, 2003-2008E Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
JAMA 303:137-43. 2010..With the exception of the American Recovery and Reinvestment Act, funding support for biomedical research in the United States has slowed after a decade of doubling. However, the extent and scope of slowing are largely unknown... 
Quantifying the risks and benefits of natalizumab in relapsing multiple sclerosisE R Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
Neurology 68:1524-8. 2007..033 QALYs (12 quality-adjusted days) gained. For context, we performed an analogous calculation for interferon beta-1a, which also had a net health benefit of 0.033 QALYs (12 quality-adjusted days)...- Financial anatomy of neuroscience researchE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, NY, USA
Ann Neurol 60:652-9. 2006..To estimate the level of funding for neuroscience research from federal and industry sources and to examine the therapeutic advances in the neurosciences over the past decade... - Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030E R Dorsey
Department of Neurology, University of Rochester Medical Center, 1351 Mt Hope Blvd, Suite 223, Rochester, NY 14620, USA
Neurology 68:384-6. 2007..The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030... - Predictors of future publication record and academic rank in a cohort of neurology residentsE Ray Dorsey
Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
Neurology 67:1335-7. 2006..01) and during (p < 0.001) residency was associated with higher post-residency publication rates. Publication differences between women and men (1.5 vs 2.4 publications/year; p = 0.03) warrant further investigation... - Biomarkers in Parkinson's diseaseE Ray Dorsey
University of Rochester Medical Center, 1351 Mt Hope Avenue, Suite 223, Rochester, NY 14620, USA
Expert Rev Neurother 6:823-31. 2006..However, to date, biomarkers, despite their considerable promise, have had limited utility in clinical trials and practice... - An evaluation of four proposals to reduce the financial burden of medical educationE Ray Dorsey
University of Rochester Medical Center, 1351 Mt Hope Ave, Suite 223, Rochester, NY 14620, USA
Acad Med 81:245-51. 2006.... - Increasing access to specialty care: a pilot, randomized controlled trial of telemedicine for Parkinson's diseaseE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 25:1652-9. 2010..Providing subspecialty care via telemedicine for individuals with Parkinson's disease living remotely is feasible... - A U.S. survey of patients with Parkinson's disease: satisfaction with medical care and support groupsE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, Rochester, New York 14620, USA
Mov Disord 25:2128-35. 2010..Specialty care and improved education, in the clinic or through support groups, may enhance satisfaction and health care quality... - Selegiline shortage: Causes and costs of a generic drug shortageE R Dorsey
Department of Neurology, University at Buffalo, NY, USA
Neurology 73:213-7. 2009..We sought to evaluate prescription trends of generic selegiline and to quantify the economic impact of any resulting drug substitution of more expensive alternatives... - Quantitative risk-benefit analysis of natalizumabJ P Thompson
Department of Neurology, University of Rochester, Rochester, NY, USA
Neurology 71:357-64. 2008..To model the long-term risks and benefits of natalizumab in individuals with relapsing multiple sclerosis (MS)... - Group patient visits for Parkinson disease: a randomized feasibility trialE R Dorsey
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA
Neurology 76:1542-7. 2011..This care delivery method has demonstrated benefits for individuals with chronic conditions but has not been evaluated for Parkinson disease (PD)... - Telemedicine for the care of nursing home residents with Parkinson's diseaseKevin M Biglan
Department of Neurology, University of Rochester Medical Center, Rochester, NY 14620, USA
Mov Disord 24:1073-6. 2009..The visits resulted in improvements in motor and cognitive symptoms and suggest that telemedicine may be useful for delivering care to this population... - Altered cholesterol and fatty acid metabolism in Huntington diseaseRobert C Block
Division of Epidemiology, Department of Community and Preventive Medicine and Preventive Cardiology Unit, Box 644, University of Rochester School of Medicine and Dentistry, 601 Elmwood Avenue, Rochester, NY 14620, USA
J Clin Lipidol 4:17-23. 2010..Drugs that combat the dysregulated lipid milieu in Huntington disease may help treat this perplexing and catastrophic genetic disease... - Local institutional review board (IRB) review of a multicenter trial: local costs without local contextBernard Ravina
Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA
Ann Neurol 67:258-60. 2010..This may be an opportune time for the National Institute of Neurological Disorders and Stroke (NINDS) to adopt a central review model... - Pivotal studies of orphan drugs approved for neurological diseasesJun Mitsumoto
College of Physicians and Surgeons, Columbia University, New York, NY, USA
Ann Neurol 66:184-90. 2009..To identify design elements of clinical trials leading to US Food and Drug Administration approval of drugs for neurological diseases with and without orphan indications... - The influence of controllable lifestyle and sex on the specialty choices of graduating U.S. medical students, 1996-2003E Ray Dorsey
University of Rochester, School of Medicine and Dentistry, 1351 Mt Hope Avenue, Suite 223, Rochester, NY 14620, USA
Acad Med 80:791-6. 2005..To determine whether the preferences of female medical students are sufficient to explain the recent trend of U.S. medical students choosing specialties with controllable lifestyles... - A randomized, placebo-controlled trial of latrepirdine in Huntington diseaseKarl Kieburtz
Department of Neurology, University of Virginia, Charlottesville, VA 22908, USA
Arch Neurol 67:154-60. 2010..To evaluate the safety and tolerability of latrepirdine in Huntington disease (HD) and explore its effects on cognition, behavior, and motor symptoms... - Impact of FDA black box advisory on antipsychotic medication useE Ray Dorsey
Department of Neurology, University of Rochester Medical Center, New York, USA
Arch Intern Med 170:96-103. 2010..The impact of these warnings on atypical drug use is unknown... - Financial anatomy of biomedical researchHamilton Moses
The Alerion Institute, North Garden, Va 22959, USA
JAMA 294:1333-42. 2005.... - Quality of life in epilepsy, multiple sclerosis, and beyondE Ray Dorsey
Ann Neurol 62:307-8. 2007 - Influence of controllable lifestyle on recent trends in specialty choice by US medical studentsE Ray Dorsey
Evanston Northwestern Healthcare, Chicago, Ill, USA
JAMA 290:1173-8. 2003..001). CONCLUSION: Perception of controllable lifestyle accounts for most of the variability in recent changing patterns in the specialty choices of graduating US medical students...